Project Details
Projekt Print View

Fighting Against Cisplatin-Resistant Tumors Using Responsive Pt(IV)/Ru(II) Bimetallic Polymers

Applicant Professor Dr. Hans-Jürgen Butt, since 12/2018
Subject Area Preparatory and Physical Chemistry of Polymers
Term from 2018 to 2021
Project identifier Deutsche Forschungsgemeinschaft (DFG) - Project number 392048923
 

Final Report Abstract

Drug resistance is a major problem in cancer treatment. In this project, we designed a dual-responsive Pt(IV)/Ru(II) bimetallic polymer (PolyPt/Ru) to treat cisplatin-resistant tumors. We demonstrated its potential application in a patient-derived xenograft (PDX) model. PolyPt/Ru is an amphiphilic ABA-type triblock copolymer. The hydrophilic A blocks consist of biocompatible poly(ethylene glycol) (PEG). The hydrophobic B block contains reduction-responsive Pt(IV) and red-light-responsive Ru(II) moieties. PolyPt/Ru self-assembles into nanoparticles that are efficiently taken up by cisplatinresistant cancer cells. Irradiation of cancer cells containing PolyPt/Ru nanoparticles with red light generates 1O2, induces polymer degradation, and triggers the release of the Ru(II) anticancer agent. Meanwhile, the anticancer drug, cisplatin, is released in the intracellular environment via reduction of the Pt(IV) moieties. The released Ru(II) anticancer agent, cisplatin, the generated 1O2 have different anticancer mechanisms. Their synergistic effects inhibit the growth of drug-resistant cancer cells. Furthermore, PolyPt/Ru nanoparticles inhibited tumor growth in a PDX mouse model because they circulate in the blood stream, accumulate at tumor sites, exhibit good biocompatibility, and does not cause side effects. Our results demonstrate that the development of stimuli-responsive multi-metallic polymers provides a new strategy to overcome drug resistance.

Publications

 
 

Additional Information

Textvergrößerung und Kontrastanpassung